Carrageenan and insulin resistance in humans: a randomised double-blind cross-over trial.

BMC Med · 2024 · PMC11590543 · PMID 39593091

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

showed a trendp = 0.06so close (0.05 < p ≤ 0.1)

after carrageenan treatments in vivo showed a trend for carrageenan-induced activation of CD19 + B cells which did not abate in the second phase of the cross-over study ( p = 0.06), while the carrageenan-induced activation of CD56 + NK cells was suggestive of carryover effects ( p = 0.06).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.